» Articles » PMID: 36920918

Progress in Scale Up of HIV Viral Load Testing in Select Sub-Saharan African Countries 2016-2018

Abstract

Introduction: We assessed progress in HIV viral load (VL) scale up across seven sub-Saharan African (SSA) countries and discussed challenges and strategies for improving VL coverage among patients on anti-retroviral therapy (ART).

Methods: A retrospective review of VL testing was conducted in Côte d'Ivoire, Kenya, Lesotho, Malawi, Namibia, Tanzania, and Uganda from January 2016 through June 2018. Data were collected and included the cumulative number of ART patients, number of patients with ≥ 1 VL test result (within the preceding 12 months), the percent of VL test results indicating viral suppression, and the mean turnaround time for VL testing.

Results: Between 2016 and 2018, the proportion of PLHIV on ART in all 7 countries increased (range 5.7%-50.2%). During the same time period, the cumulative number of patients with one or more VL test increased from 22,996 to 917,980. Overall, viral suppression rates exceeded 85% for all countries except for Côte d'Ivoire at 78% by June 2018. Reported turnaround times for VL testing results improved in 5 out of 7 countries by between 5.4 days and 27.5 days.

Conclusions: These data demonstrate that remarkable progress has been made in the scale-up of HIV VL testing in the seven SSA countries.

Citing Articles

Biological and Social Predictors of HIV-1 RNA Viral Suppression in ART Treated PWLH in Sub-Saharan Africa.

Gandla S, Nakka R, Khan R, Bose E, Ghebremichael M Trop Med Infect Dis. 2025; 10(1).

PMID: 39852675 PMC: 11768424. DOI: 10.3390/tropicalmed10010024.


HIV clinical outcomes among people with HIV and diabetes mellitus in Kampala, Uganda; A matched retrospective cohort study.

Nakalega R, Semitala F, Mutebi E, Mawanda D, Lukyamuzi Z, Menge R PLOS Glob Public Health. 2025; 5(1):e0003922.

PMID: 39820139 PMC: 11737773. DOI: 10.1371/journal.pgph.0003922.


Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.

Ambe Chenwi C, Nayang Mundo R, Nka A, Ngoufack Jagni Semengue E, Beloumou G, Kae A J Int Assoc Provid AIDS Care. 2024; 23:23259582241306484.

PMID: 39711049 PMC: 11664513. DOI: 10.1177/23259582241306484.


Challenges and Ongoing Actions to Address the Mpox Emergency in Africa.

Rahim F, Fallah M, Jain U, Richardson E, Ndembi N, Ngongo N Ann Glob Health. 2024; 90(1):68.

PMID: 39554695 PMC: 11568800. DOI: 10.5334/aogh.4580.

References
1.
Toni T, Masquelier B, Lazaro E, Dore-Mbami M, Ba-Gomis F, Tea-Diop Y . Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses. 2005; 21(12):1031-4. DOI: 10.1089/aid.2005.21.1031. View

2.
Lecher S, Fonjungo P, Ellenberger D, Toure C, Alemnji G, Bowen N . HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018. MMWR Morb Mortal Wkly Rep. 2021; 70(21):775-778. PMC: 8158895. DOI: 10.15585/mmwr.mm7021a2. View

3.
Nkengasong J, Mbopi-Keou F, Peeling R, Yao K, Zeh C, Schneidman M . Laboratory medicine in Africa since 2008: then, now, and the future. Lancet Infect Dis. 2018; 18(11):e362-e367. DOI: 10.1016/S1473-3099(18)30120-8. View

4.
Alemnji G, Peter T, Vojnov L, Alexander H, Zeh C, Cohn J . Building and Sustaining Optimized Diagnostic Networks to Scale-up HIV Viral Load and Early Infant Diagnosis. J Acquir Immune Defic Syndr. 2020; 84 Suppl 1:S56-S62. DOI: 10.1097/QAI.0000000000002367. View

5.
Galvani A, Pandey A, Fitzpatrick M, Medlock J, Gray G . Defining control of HIV epidemics. Lancet HIV. 2018; 5(11):e667-e670. DOI: 10.1016/S2352-3018(18)30178-4. View